Withdrawal of Immunosuppression
in Pediatric Liver Transplant Recipients in Korea

Jee Hyun Lee,1 Suk-Koo Lee,2 Hae Jeong Lee,3 Jeong Meen Seo,2 Jae Won Joh,2 Sung Joo Kim,2
Choon Hyuck Kwon,2 and Yon Ho Choe3

1Department of Pediatrics, Kangnam Sacred Heart Hospital, Hallym University School of Medicine, Seoul;
Departments of 2Surgery and 3Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Purpose: We identified pediatric liver transplant recipients with successful withdrawal of immunosuppression who developed tolerance in Korea. Materials and Methods: Among 105 pediatric patients who received liver transplantation and were treated with tacrolimus-based immunosuppressive regimens, we selected five (4.8%) patients who had very low tacrolimus trough levels. Four of them were noncompliant with their medication and one was weaned off of immunosuppression due to life threatening posttransplant lymphoproliferative disorder. We reviewed the medical records with regard to the relationship of the donor-recipient, patient characteristics and prognosis, including liver histology, and compared our data with previous reports. Results: Four patients received the liver transplantation from a parent donor and one patient from a cadaver donor. A trial of withdrawal of the immunosuppressant was started a median of 45 months after transplantation (range, 14 months to 60 months), and the period of follow up after weaning from the immunosuppressant was a median of 32 months (range, 14 months to 82 months). None of the five patients had rejection episodes after withdrawal of the immunosuppression; they maintained normal graft function for longer than 3 years (median, 38 months; range, 4 to 53 months). The histological findings of two grafts 64 and 32 months after weaning-off of the medication showed no evidence of chronic rejection. Conclusion: The favorable markers for successful withdrawal of immunosuppression were 1) long-term (> 3 years) stable graft function, 2) no rejection for longer than 1 year after withdrawal of immunosuppression, 3) non-immune mediated liver diseases, and 4) pediatric patients.

Key Words: Pediatric liver transplantation, withdrawal of immunosuppression, tacrolimus

INTRODUCTION

As survival has improved after liver transplantation, with potent immunosuppressants like tacrolimus, the quality of life and long-term immunosuppression have become important factors in addition to acute rejection and graft survival. There are reports on liver transplant recipients who acquire tolerance.1 We identified pediatric liver transplant recipients with successful withdrawal of immunosuppression who developed tolerance and analyzed the patient characteristics, donor-recipient relationship, immunosuppressant regimens, and prognosis.

MATERIALS AND METHODS

From April 1997 to July 2007, 105 pediatric liver transplantation recipients received tacrolimus-based immunosuppression at Samsung Medical Center,

© Copyright: Yonsei University College of Medicine 2009
Seoul, Korea. Among them, we selected five patients (4.8%) who had a very low tacrolimus trough level (< 1 ng/mL by Liquid Chromatography-Mass Spectrometry/MS). Four of them had frequently refused to take the immunosuppressive drug; they were interviewed to confirm the noncompliance. Finally, four patients weaned due to noncompliance and one patient weaned due to life threatening posttransplant lymphoproliferative disorder (PTLD) were enrolled. The median age at transplantation was three years (range, 8 months to 9 years). The primary diseases were biliary atresia (n = 2), neonatal hepatitis of unknown cause (n = 1) and hepatocellular carcinoma (n = 2). Four patients received living-related liver transplantation from their parent and one patient received a cadaver transplant. All five patients underwent immunosuppression induced with a steroid and tacrolimus regimen during the early stage of liver transplantation and were maintained on tacrolimus-based immunosuppression. Monitoring of graft function was followed by blood tests to assess liver function. In cases of abnormal findings in the blood tests, suspicion of rejection, a liver biopsy was performed.

We reviewed the medical records and analyzed the clinical characteristics of the patients who discontinued immunosuppression, and retrospectively evaluated the immunologic relationship with their donor (blood type), immunologic status of a specific virus at pre-transplantation [Ebstein-Barr Virus (EBV), cytomegalovirus (CMV)], time between transplantation and immunosuppressant withdrawal, follow-up period after immunosuppressant withdrawal, episodes of rejection, and graft function. In addition, we attempted to confirm their histological graft status by performing a liver biopsy in two of the patients 64 and 32 months after withdrawal of immunosuppression.

RESULTS

Four patients received the liver transplantation from a parent donor and one patient from a cadaver donor. The immunosuppression regimen was steroid and tacrolimus treatment for a median of six months (range, 2 months to 9 months) after transplantation, followed by maintenance with tacrolimus for a median of 38 months (range, 4 months to 53 months) (Fig. 1). During the maintenance period, all patients had stable liver function. Three patients were treated with pulse steroid therapy and dose up tacrolimus therapy when there was suspicion of acute rejection; two patients were confirmed to have acute rejection by liver biopsy within a month after transplantation. None of the five patients had rejection episodes for over 1 year (range, 14 months to 82 months) after withdrawal of the immunosuppression.

Among the five cases, there were ABO blood type-identical grafts in three cases and compatible grafts in two. Three patients were EBV high-risk (EBV seronegative recipients from EBV seropositive donor); one of them developed life threatening gastrointestinal PTLD and was weaned off immunosuppression 14 months post-transplantation. All five patients were CMV IgG positive pre-transplantation; there were no complications associated with CMV infection throughout the follow-up after transplantation (Table 1).

A trial of withdrawal of immunosuppressant was started a median of 45 months after transplantation (range, 14

Table 1. Characteristics of the Subjects

| Case No. | Diagnosis       | Sex | Age at transplantation | Donor | Blood type (R/D) | EBV risk group | Pre LT CMV status (IgG / IgM) |
|----------|----------------|-----|------------------------|-------|-----------------|----------------|-----------------------------|
| 1        | Biliary atresia| F    | 2 yrs                  | Father| O+ / O+ (identical) | High           | (+ / -)                     |
| 2        | Neonatal hepatitis| M   | 8 months              | Mother| B+ / O+ (compatible) | High           | (+ / -)                     |
| 3        | Biliary atresia| M    | 3 yrs                  | Father| A+ / O+ (compatible) | Low            | (+ / -)                     |
| 4        | HCC (HBV)      | M    | 9 yrs                  | Father| B+ / B+ (identical) | High           | (+ / -)                     |
| 5        | HCC (HBV)      | M    | 8 yrs                  | Cadaver| O+ / O+ (identical) | Low            | (+ / -)                     |

HCC, hepatocellular carcinoma; R, recipient; D, donor; EBV, Ebstein-Barr Virus; CMV, cytomegalovirus.

EBV high-risk group: EBV-seronegative patients receiving allograft from EBV-seropositive donors.

EBV low-risk group: EBV-seronegative recipient or EBV-seronegative patients receiving allograft from EBV-seronegative donors.

Fig. 1. Immunosuppressant regimens and withdrawal process.
months to 60 months), and the period of follow up after weaning from the immunosuppressant was a median of 32 months (range, 14 months to 82 months). None of the five patients had rejection episodes after withdrawal of immunosuppression; four of them maintained normal graft function for longer than 3 years (median, 38 months; range, 4 to 53 months) (Table 2). There was no case of an immune-mediated primary liver disease. Two of the four noncompliant patients (patient 1 and 3) were intentionally weaned from their medication. The main reason for weaning off the immunosuppression was parents’ anxiety about the complications from immunosuppression therapy. The other two noncompliant patients (patient 4 and 5) had taken the medication irregularly. These two older children refused to take the life-long medication.

We compared these five patients with previous reports to determine the favorable clinical markers and selection criteria for discontinuation of immunosuppression (Table 3). Devlin, et al.² and Takatsuki, et al.³ reported on the withdrawal of immunosuppression, including pediatric liver transplant recipients, and analyzed the favorable markers for successful withdrawal of immunosuppression and the selection criteria for elective weaning. The five patients reported here had non-immune mediated primary liver disease, long-term maintenance of normal graft function without rejection and were all pediatric recipients. Excluding the one patient with PTLD, four patients attempted to wean the immunosuppressant treatment two years post-transplantation.

We performed a liver biopsy in two of our patients at 64 months and 32 months after withdrawal of the immunosuppressant. Hepatic lobular architecture is well preserved showing focal ballooning degeneration. Portal space displays intact bile ducts with no inflammatory infiltrate. Mild perportal fibrosis is found (original magnification ×200, Masson Trichrome).

**DISCUSSION**

Tolerance is defined as the clinical situation when a graft

---

**Table 2. Outcome after Weaning of Immunosuppression**

| Case No. | Cause of IS withdrawal | Maintenance IS | Time between LT and weaning | Follow-up after IS weaning | Rejection* (n) | The last AST / ALT / GGT (U/L) |
|----------|------------------------|----------------|-----------------------------|---------------------------|---------------|-------------------------------|
| 1        | Noncompliance          | Tacrolimus     | 60 months                   | 64 months                 | 0             | 28 / 25 / 10                 |
| 2        | PTLD                   | Tacrolimus     | 14 months                   | 82 months                 | 1             | 33 / 26 / 32                 |
| 3        | Noncompliance          | Tacrolimus     | 60 months                   | 32 months                 | 1             | 23 / 14 / 24                 |
| 4        | Noncompliance          | Tacrolimus     | 45 months                   | 14 months                 | 0             | 28 / 17 / 12                 |
| 5        | Noncompliance          | Tacrolimus     | 41 months                   | 29 months                 | 0             | 21 / 12 / 16                 |

IS, immunosuppressant; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl transferase.

*Rejection before weaning of immunosuppression.

**Table 3. Comparison of Favorable Clinical Markers for Withdrawal of Immunosuppression**

| Suggested factors for withdrawal in the previous studies | Subjects included in this study |
|--------------------------------------------------------|---------------------------------|
| Author                                                 | Case1 | Case2 | Case3 | Case4 | Case5 | %   |
| Devlin, et al.                                          |       |       |       |       |       |     |
| > 5 years post-LT                                       | O     | X     | X     | O     | X     | 40  |
| Non-immune mediated liver disorders                     | O     | O     | O     | O     | O     | 100 |
| Incidence of early rejection (n)                        | 0     | 1     | 1     | 0     | 0     | -   |
| Takatsuki, et al.                                       |       |       |       |       |       |     |
| > 2 years post-LT                                       | O     | X     | X     | O     | O     | 80  |
| Long-term normal graft function                         | O     | O     | O     | O     | O     | 100 |
| > 1 year without rejection after withdrawal            | O     | O     | O     | O     | O     | 100 |
| LDLT                                                   | O     | O     | O     | X     |       | 80  |
| Pediatric case                                          | O     | O     | O     | O     |       | 100 |

LDLT, living-donor liver transplantation.
maintains stable function without the need for chronic immunosuppression; it occurs more frequently in liver allografts than with other solid organ transplantation. Some reports support elective immunosuppressive drug weaning for selected liver transplant recipients. It is thought that donor cell chimerism is associated with donor specific tolerance and allograft acceptance. Studies reporting on the possibility of these hypotheses have not revealed the exact mechanism underlying tolerance. Thomson, et al. attempted to evaluate the validity of immunologic and biologic tests that correlated with and were predictive of a state of tolerance. They analyzed dendritic cell types, cytokine secretion, donor specific antibody prevalence, and cytokine genotypes, however, failed to identify any clinically useful markers. Mazariego, et al. suggested that an increased ratio of plasmacytoid dendritic cell to myeloid dendritic cell was a significant factor for achieving operational tolerance. Therefore, the mechanism underlying tolerance is not known, and there have been no large-scale studies of elective weaning off of immunosuppressant treatment. There are only a limited number of studies on accidentally weaned noncompliant patients and withdrawal of immunosuppressant due to severe infection or PTLD, or small groups of selectively chosen patients for elective weaning at certain centers.

Mazariego, et al. reported that azathioprine/prednisone and tacrolimus-based treatments of patients were more likely to be off drugs at one year after transplantation compared to ciclosporine treated patients, and Takatsuki, et al. suggested that the graft survival was better in patients who received a living-related donor transplantation. Lerut, et al. reviewed reports on the withdrawal of immunosuppression and found that immunosuppression withdrawal is possible in 19.4% of transplant recipients, and that the common favorable clinical markers were: 1) an age > two years post liver transplantation, 2) a low incidence of rejection, 3) non-immune mediated liver disease, and 4) minimal immunosuppression. Most of the prospective elective withdrawal studies included patients followed for longer than two years. However, Eason, et al. enrolled patients with less than six months of follow-up, and only one of their eighteen patients was weaned off the immunosuppression successfully. Therefore, it remains unclear when immunosuppression can safely be withdrawn.

Some reports have raised concerns about chronic rejection after withdrawal of immunosuppression. Koshiba, et al. reported that liver biopsy after complete withdrawal of the immunosuppressant revealed changes of the bile duct and fibrosis. However, there were no such findings in our study.

The five patients included in this study had long-term (> 3 years) stable graft function, no rejection for more than 1 year after withdrawal of immunosuppression, non-immune mediated liver diseases, and were all pediatric cases; all of these factors are favorable markers, according to previous reports. Although a small number of patients were studied, this is the first report on tolerance in pediatric liver transplant recipients in Korea after withdrawal of immunosuppression. To improve the quality of life for liver transplant recipients, confirmation of our findings with a multicenter trial is now needed to determine patient factors, clinical timing and biological markers associated with successful immunosuppressant withdrawal.

REFERENCES

1. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006;6:1774-80.
2. Devlin J, Doherty D, Thomson L, Wong T, Donaldson P, Portmann B, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998;27:926-33.
3. Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuichi T, Fujita S, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001;72:449-54.
4. Thomson AW, Mazariegos GV, Reyes J, Donnenberg VS, Donnenberg AD, Bentlejewski C, et al. Monitoring the patient off immunosuppression. Conceptual framework for a proposed tolerance assay study in liver transplant recipients. Transplantation 2001;72 (8 Suppl):S13-22.
5. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet 1992;339:1579-82.
6. Pons JA, Yelamos J, Ramirez P, Oliver-Bonet M, Sanchez A, Rodriguez-Gago M, et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 2003;75:1045-7.
7. Tryphonopoulos P, Tkakis AG, Weppler D, Garcia-Morales R, Kato T, Madariaga JR, et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allograft transplantation. Am J Transplant 2005;5:608-13.
8. Mazariegos GV, Zahorhach AF, Reyes J, Ostrowski L, Flynn B, Zeevi A, et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 2003;3:689-96.
9. Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant 2004;8:207-72.
10. Eason JD, Cohen AJ, Nair S, Alcantera T, Loss GE. Tolerance: is it worth the risk? Transplantation 2005;79:1157-9.
11. Massarollo PC, Mies S, Abdala E, Letião RM, Raia S. Immunosuppression withdrawal for treatment of severe infections in liver transplantation. Transplant Proc 1998;30:1472-4.
12. Mazariegos GV, Reyes J, Marino I, Flynn B, Fang JJ, Starzl TE. Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. Transplant Proc 1997;29:1174-7.
13. Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997;63:243-9.
14. Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006;44:702-9.

15. Sebagh M, Rifai K, Féray C, Yilmaz F, Falissard B, Roche B, et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003;37:1293-301.

16. Koshiba T, Li Y, Takemura M, Wu Y, Sakauchi S, Minato N, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007;17:94-7.